
Paradigm Biopharmaceuticals Ltd
ASX:PAR

Intrinsic Value
The intrinsic value of one
PAR
stock under the Base Case scenario is
0.16
AUD.
Compared to the current market price of 0.29 AUD,
Paradigm Biopharmaceuticals Ltd
is
Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Paradigm Biopharmaceuticals Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Paradigm Biopharmaceuticals Ltd
Balance Sheet Decomposition
Paradigm Biopharmaceuticals Ltd
Current Assets | 32.3m |
Cash & Short-Term Investments | 24.8m |
Receivables | 6.4m |
Other Current Assets | 1.1m |
Non-Current Assets | 3.1m |
PP&E | 118.2k |
Intangibles | 2.9m |
Free Cash Flow Analysis
Paradigm Biopharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Paradigm Biopharmaceuticals Ltd
Revenue
|
5.7m
AUD
|
Cost of Revenue
|
-27.7k
AUD
|
Gross Profit
|
5.7m
AUD
|
Operating Expenses
|
-21.3m
AUD
|
Operating Income
|
-15.6m
AUD
|
Other Expenses
|
30.5k
AUD
|
Net Income
|
-15.6m
AUD
|
PAR Profitability Score
Profitability Due Diligence
Paradigm Biopharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Paradigm Biopharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
PAR Solvency Score
Solvency Due Diligence
Paradigm Biopharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Score
Paradigm Biopharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PAR Price Targets Summary
Paradigm Biopharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
PAR
is 0.82 AUD
with a low forecast of 0.81 AUD and a high forecast of 0.84 AUD.
Dividends
Current shareholder yield for PAR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PAR
stock under the Base Case scenario is
0.16
AUD.
Compared to the current market price of 0.29 AUD,
Paradigm Biopharmaceuticals Ltd
is
Overvalued by 45%.